Prostate cancer DNA vaccine (Genvax/University of Southampton)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameProstate cancer DNA vaccine (Genvax/University of Southampton)
Drug Alias NameElectroporation-delivered DNA vaccine against prostate cancer - Inovio/University of SouthamptonGVX-3322
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInovio Pharmaceuticals IncUniversity Of Southampton
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInovio Pharmaceuticals IncGenvaxUniversity Of Southampton
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A